PANoptosis in diabetic retinopathy: immunological insights into mechanisms and translational therapies
Frontiers in Immunology · 19.06.2026 · 17
DOI: 10.3389/fimmu.2026.1668099 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Immunology, online erschienen am 19.06.2026. Verfasst von Lingli Ma und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of endocrinology and metabolism, China-Japan Union Hospital of Jilin University, Changchun, China. Hauptthemen laut MEDLINE: Diabetic Retinopathy, Necroptosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 182 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Diabetic retinopathy (DR), a leading cause of blindness, is driven by hyperglycemia-induced neurovascular damage. Emerging evidence indicates that PANoptosis, an integrated inflammatory programmed cell death modality encompassing apoptosis, pyroptosis, and necroptosis, participates in the progression of diabetic retinal damage; however, the supporting evidence varies substantially across clinical specimens, diabetic animal models, high-glucose cultured retinal cells, and non-DR inflammatory disease models. This review systematically summarizes the latest advances in PANoptosis-associated mechanisms underlying DR pathogenesis, focusing on PANoptosome signaling networks, non-coding RNA-mediated regulation, and immune-metabolic crosstalk. We outline promising candidate biomarkers including PANoptosis-related gene signatures and inflammatory cell death molecules, and critically evaluate multiple translational therapeutic strategies covering small-molecule inhibitors, gene intervention, and nanomedicine delivery. Importantly, we further address context-dependent dual roles of PANoptosis, potential safety risks of non-selective PANoptosis blockade, challenges in blood–retinal barrier penetration, systemic immune side effects, and pathological heterogeneity among DR subtypes and disease stages. Since PANoptosis also fundamentally contributes to host defense and retinal innate immune homeostasis, DR therapeutic strategies should prioritize biomarker-guided, local ocular delivery, time-dependent stage intervention, and cell-type-specific fine tuning, rather than generalized systemic suppression. By reconciling mechanistic progress with unresolved translational bottlenecks, this review proposes that PANoptosis serves as a dynamic and evolving conceptual framework for interpreting inflammatory neurovascular degeneration in DR, instead of an entirely confirmed clinical therapeutic target. We emphasize the urgent need for DR-specific mechanistic verification, longitudinal biomarker cohort studies, and well-designed multicenter clinical trials to advance safe and precise targeted interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of endocrinology and metabolism, China-Japan Union Hospital of Jilin University, Changchun, China.
- Department of Cardiac Superficial Musculoskeletal Ultrasound, Songyuan Central Hospital, Songyuan, China.
Zitieren
APA
Ma, L., Hou, N., Zhao, X., Li, Z., Liu, Q., Zhao, J., & Wang, Q. (2026). PANoptosis in diabetic retinopathy: immunological insights into mechanisms and translational therapies. Frontiers in Immunology, 17. https://doi.org/10.3389/fimmu.2026.1668099
Vancouver
Ma L, Hou N, Zhao X, Li Z, Liu Q, Zhao J, et al. PANoptosis in diabetic retinopathy: immunological insights into mechanisms and translational therapies. Frontiers in Immunology. 2026;17. doi:10.3389/fimmu.2026.1668099
BibTeX
@article{Ma2026,
author = {Ma, Lingli and Hou, Ning and Zhao, Xiaoyu and Li, Zimeng and Liu, Qing and Zhao, Jianyu and Wang, Qing},
title = {PANoptosis in diabetic retinopathy: immunological insights into mechanisms and translational therapies},
journal = {Frontiers in Immunology},
year = {2026},
volume = {17},
doi = {10.3389/fimmu.2026.1668099}
}
EUVIMED